Intarcia Therapeutics

aid: intarcia-therapeutics
name: Intarcia Therapeutics
description: 'Intarcia Therapeutics, Inc. was a Boston-headquartered clinical-stage biopharmaceutical and drug-delivery company,
  founded in 1997 and once valued at roughly $5.5B, that developed the Medici Drug Delivery System — a matchstick-sized subdermal
  osmotic mini-pump engineered to stabilize therapeutic proteins and peptides at body temperature and release them continuously
  for months from a single placement. Its lead candidate, ITCA 650, delivered the GLP-1 receptor agonist exenatide for type
  2 diabetes over three- to six-month intervals. The FDA issued complete response letters on the ITCA 650 new drug application
  in 2017 and again in 2020, after which the company ran out of capital, laid off staff, closed its Boston, Hayward (CA) and
  Durham (NC) sites and liquidated its manufacturing and laboratory equipment at auction. Its remaining assets — the Medici
  platform and ITCA 650 — were acquired by i2o Therapeutics in August 2023, and FDA published a final decision refusing to
  approve the ITCA 650 application on 2024-08-23. Intarcia was a drug-device developer rather than a software company: its
  corporate site carried only Medici System, Pipeline, Newsroom, About, Leadership and Careers sections and never published
  a developer program, public API, SDK, webhook surface or machine-readable specification of any kind. As of 2026-08-23 both
  intarcia.com and intarciatherapeutics.com resolve to an Atom.com domain-broker parking page that offers the names for sale
  and returns HTTP 404 on every path, and no developer-facing subdomain resolves. This profile is retained as a historical
  record; there is no API surface to enrich.'
url: https://raw.githubusercontent.com/api-evangelist/intarcia-therapeutics/refs/heads/main/apis.yml
x-api-posture: no-product-api
x-api-posture-basis: observed
x-api-posture-note: 'Intarcia was a drug-device developer rather than a software company: its corporate site carried only
  Medici System, Pipeline, Newsroom, About, Leadership and Careers sections and never published a dev'
x-type: company
x-source: harvest:secondary-market
x-secondary-market-listing: https://forgeglobal.com/intarcia-therapeutics_stock/
x-tier: stub
x-tier-reason: defunct-no-api-surface
x-status: defunct
x-shutdown-note: Wound down after the FDA's second complete response letter in 2020; equipment liquidated at auction and the
  Medici / ITCA 650 assets acquired by i2o Therapeutics in August 2023. FDA published its final decision refusing approval
  of ITCA 650 on 2024-08-23.
x-successor: i2o Therapeutics (acquired the Medici Drug Delivery System and ITCA 650, 2023-08)
x-domain-status: parked-for-sale
x-domain-note: intarcia.com and intarciatherapeutics.com both resolve to 52.20.84.62 on ns1/ns2.atom.com and serve an Atom.com
  domain-broker landing page. Every /.well-known/ and spec path returns a hard HTTP 404 (679 bytes, identical to a nonsense
  control path), so there are no soft-200 false positives to guard against. These hosts are NOT company-controlled and are
  deliberately not wired as a Website pointer. See well-known/intarcia-therapeutics-well-known.yml.
x-venue-listing-note: The Forge Global secondary-market page this company was harvested from is recorded above as x-secondary-market-listing
  and is deliberately NOT wired as a common[] Website pointer — a trading-venue listing is not a company web presence (network
  roadmap#56).
deliveryModel:
  model: unknown
  open_source: false
  commercial: false
  callable_host: false
  label: Delivery model not determined — needs a product licence on record
  confidence: low
  source:
  - none
  generated: '2026-08-28'
  method: derived
specificationVersion: '0.23'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Defunct
- Biotechnology
- Pharmaceuticals
- Drug Delivery
- Medical Devices
- Diabetes
- Health
- Life Sciences
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common: []
x-coverage:
  state: none
  reason: defunct
  detail: Intarcia Therapeutics wound down after the FDA's 2020 complete response letter and sold the Medici / ITCA 650 assets
    to i2o Therapeutics in 2023; intarcia.com and intarciatherapeutics.com are now an Atom.com domain-broker parking page
    that hard-404s every /.well-known/ and spec path, and api., developer., docs., portal., dev. and app. subdomains do not
    resolve at all.
  evidence:
  - url: https://intarcia.com/
    status: 403
  - url: https://intarcia.com/zzz-control-nonsense-xyz789
    status: 404
  - url: https://intarcia.com/openapi.json
    status: 404
  - url: https://intarcia.com/llms.txt
    status: 404
  - url: https://intarcia.com/.well-known/agent-card.json
    status: 404
  - url: https://intarciatherapeutics.com/.well-known/agent.json
    status: 404
  - url: https://api.github.com/orgs/intarcia
    status: 200
  - url: https://forgeglobal.com/intarcia-therapeutics_stock/
    status: 403
  checked: '2026-08-23'
x-enrichment:
  date: '2026-08-23'
  status: nochange
  artifacts_added: 1
  pass: local-v1